Wanyu Tang
Xudong Tian*†- Department of Health Medicine, Chongqing Youth Vocational and Technical College, Chongqing, China
Patient-derived organoids (PDOs) have emerged as transformative preclinical models in non-small cell lung cancer (NSCLC), offering high-fidelity recapitulation of tumor heterogeneity and drug responses. Compared to traditional cell lines and xenografts, PDOs preserve the genetic, phenotypic, and functional features of parental tumors, enabling precise drug sensitivity testing for chemotherapy, targeted therapy, and immunotherapy, particularly through optimized culture protocols, genetic engineering techniques, and cryopreservation methods, have significantly enhanced their scalability and clinical relevance. PDOs have proven instrumental in elucidating key resistance mechanisms such as EGFR-TKI resistance mediated through DCLK1-dependent Wnt signaling activation, while simultaneously identifying novel therapeutic synergies for clinical translatio. However, challenges remain in modeling the tumor immune microenvironment and standardizing clinical translation. This review systematically outlines the advancements and challenges in establishing NSCLC PDOs, highlights the potential of PDOs to guide personalized NSCLC therapy while addressing current limitations to bridge the gap between research and clinical application.
1 Introduction
Lung cancer remains one of the most prevalent and lethal malignancies worldwide (Dijkstra et al., 2025). This poor prognosis is largely attributable to the genomic instability of tumor cells, which leads to both germline and somatic mutations, thereby fostering pronounced inter- and intra-tumoral heterogeneity and therapeutic resistance (Canale et al., 2025; Nousias et al., 2025; Kobay et al., 2023). The identification of suitable experimental models for drug sensitivity screening represents a promising strategy for precision therapy. Beyond empiric treatment paradigms, individualized drug susceptibility testing may enable the selection of optimal therapeutic agents, thereby improving clinical outcomes. Traditional anti-cancer drug screening systems primarily rely on patient-derived tumor cell (PDC) models and patient-derived xenograft (PDX) models. The PDC model offers several advantages, including rapid proliferation, low maintenance cost, and amenability to functional assays, and has thus been widely employed in high-throughput drug screening platforms (Xu et al., 2022; Ma et al., 2022a). However, PDCs fail to faithfully recapitulate the phenotypic and genetic complexities of in vivo tumors and cannot accurately model the dynamic progression and heterogeneity of cancer. In contrast, PDX models preserve the tumor microenvironment, histopathological architecture, and genomic landscape of the parental tumor, rendering them valuable tools for anti-cancer drug screening, and for predicting therapeutic efficacy, toxicity, adverse events, and drug bioavailability. Nonetheless, the generation of PDX models is dependent on immunocompromised murine hosts, which differ significantly from humans in both genetic and biological contexts (LeSavage et al., 2022).
Patient-derived organoids (PDOs) represent a novel class of 3D miniature tumor models derived from primary tumor tissues harvested directly from patients (Wang et al., 2022; Li and Izpisua Belmonte, 2019). These models retain the essential histopathological, genetic, and phenotypic attributes of the parental tumors. Compared to PDC and PDX models, PDOs can be established within microenvironments that more closely approximate physiological conditions, thereby supporting faithful phenotypic replication and robust tumor cell proliferation (Drost and Clevers, 2018; Rossi et al., 2022). Given their high fidelity in recapitulating the histological and functional characteristics of the original tumors, PDOs have found broad applications in regenerative medicine and mechanistic disease research. In the context of lung cancer, PDOs serve as innovative ex vivo models capable of recapitulating the biological features of primary tumors with high precision. When co-cultured with extracellular matrix components and stromal elements, they further enable the reconstruction of the tumor microenvironment (Li and Izpisua Belmonte, 2019). These attributes make lung cancer PDOs a potentially powerful tool for drug sensitivity testing and for advancing personalized treatment strategies. Although the utility of lung cancer patient-derived organoids (PDOs) has been reviewed from multiple perspectives (Navarro et al., 2025), systematic and in-depth evaluations of their role in guiding individualized therapy remain limited. While preliminary studies demonstrate that lung cancer PDOs show promise in drug sensitivity assays for clinical decision-making (Adhikary et al., 2025), most investigations have assessed only a narrow spectrum of therapeutic agents. This review highlights the innovative advantages of lung cancer PDOs, focusing specifically on recent advances in their application as drug sensitivity testing platforms for conventional chemotherapeutics, targeted agents, and immunotherapies. Furthermore, this review outlines the current limitations to provide a balanced perspective on the potential and challenges of PDOs in lung cancer treatment.
2 Establishment and optimization of NSCLC organoid models
2.1 Technical challenges in organoid derivation
NSCLC organoids are predominantly established from surgical tumor specimens (Ma J. et al., 2025). Typically, tissues are mechanically dissociated into small fragments and digested enzymatically using collagenase or neutral protease at 37 °C to yield single cells or small clusters, which are subsequently cultured to form NSCLC organoids (Kim and Park, 2025). To improve tumor cell purity and better recapitulate tumor heterogeneity, Li Z. et al. (2021) optimized the use of minimally invasive biopsy specimens or malignant pleural effusions, reducing contamination from normal pulmonary cells. The efficiency of tumor cell isolation depends critically on enzymatic digestion parameters, including enzyme type, concentration, digestion mode, and duration, which influence both cell yield and viability. To mitigate enzymatic damage to tumor cells, preserve tissue integrity, and streamline cell isolation, Tamura et al. (2018) and Takahashi et al. (2019) developed a method using mechanically minced tumor tissue for suspension culture. After stromal depletion, prolonged culture (3–6 months) in matrix-free medium yielded a biobank of 15 NSCLC organoids. Li Z. et al. (2021), Li Z. et al. (2020) observed that some NSCLC organoids exhibit limited proliferative capacity after serial passaging, regardless of enzymatic conditions. Alternative protocols (Li et al., 2018; Sachs et al., 2019) addressed this by employing mechanical dissociation during passaging, fragmenting organoids without enzymatic treatment, thereby improving long-term expansion. Further refinements in organoid handling have enhanced practicality. Kim et al. (2019) identified organoid diameter (100–150 μm) and storage temperature (4 °C) as critical factors for cryopreservation, achieving 70% post-thaw recovery via low-speed centrifugation and liquid nitrogen storage. Compared to 2D cultures, the 3D complexity of PDOs introduces additional challenges. To streamline culture conditions, Zhang et al. (2016) designed a superhydrophobic microwell array chip that isolates organoids using hydrophobic microstructures. This platform simplifies medium exchange, improves viability, and increases culture success rates by reducing technical variability.
Another critical challenge in the establishment of NSCLC organoids is the maintenance of genetic stability over prolonged culture periods (Li Z. et al., 2024). As organoids undergo long-term expansion, genetic drift that manifested as the accumulation of somatic mutations and chromosomal aberrations can occur, potentially altering the tumor’s genomic landscape (Nam et al., 2022). This genetic instability can profoundly impact drug response data by introducing mutations that confer resistance to certain therapies or enhance sensitivity to others (Broutier et al., 2017). For instance, mutations in the EGFR signaling pathway, such as the acquisition of the T790M mutation, could render organoids resistant to EGFR inhibitors, despite initial sensitivity (Lim et al., 2024). Similarly, mutations in KRAS, particularly G12C, could alter the tumor’s response to targeted therapies like EGFR-TKIs and MEK inhibitors by activating downstream MAPK and PI3K/AKT/mTOR pathways that promote tumor survival and drug resistance (Song et al., 2024; Ma X. et al., 2025). Genetic drift may also activate the Wnt/β-catenin pathway, which regulates tumor progression and stem cell maintenance, further contributing to therapy resistance (Yan et al., 2022). Additionally, ferroptosis, a regulated form of cell death suppressed by genetic alterations such as GPX4 loss (Liao et al., 2024), may be dysregulated in PDOs, particularly those exposed to chemotherapy, leading to enhanced resistance. These alterations, driven by genetic drift, underscore the potential for PDOs to evolve differently from the original tumor, complicating the predictive value of drug response assays. Therefore, long-term culture-induced genetic drift must be carefully considered when interpreting PDO-based drug sensitivity data.
2.2 Current frontiers in NSCLC organoid systems
A critical challenge in establishing NSCLC organoids from surgical specimens is the overgrowth of normal cells, which reduces tumor purity (Lee et al., 2021). To address this, Kumamot et al. (2008) found that nutlin-3a supplementation selectively eliminates non-tumor cells, promoting the expansion of TP53-mutant organoids. However, prolonged use of such agents may induce genomic instability and alter tumor-specific characteristics (Kucab et al., 2017). Alternative approaches, such as embedding dissociated tumor cells in matrigel with lung epithelial-optimized media, have proven more effective in suppressing normal cell growth while preserving cancer genomic integrity (Kim et al., 2019; Shi et al., 2020). Recent advances focus on leveraging organoids for personalized therapy (Han et al., 2022; Kim SK. et al., 2021). For instance, Banda et al. (2020) cultured organoids in erlotinib-containing matrigel, monitoring genomic evolution and resistance mechanisms. Their findings recapitulated acquired resistance in NSCLC, providing insights for therapeutic optimization. Beyond primary tumor-derived models, genetically engineered normal organoids offer a controlled system to study carcinogenesis. Naranjo et al. (2022) induced oncogenic mutations in normal lung organoids, triggering malignant transformation and tumor formation upon murine transplantation. Similarly, Dost et al. (2020) generated KRAS-mutant organoids, which exhibited diminished epithelial biomarker expression, validating their use in early-stage cancer modeling. While 3D matrigel-based systems (Shi et al., 2020) facilitate tumor-specific studies, their lack of native stromal and immune components restricts microenvironmental recapitulation (Yuki et al., 2020). Consequently, co-culture models integrating tumor organoids and immune cells are emerging as a vital tool to investigate tumor-immune crosstalk, potentially advancing NSCLC immunotherapy research (Dijkstra et al., 2018; Nakamura et al., 2019).
3 Applications of NSCLC organoids in drug screening
Organoid models have emerged as a transformative tool for recapitulating critical features of tumor biology. As patient-derived systems, they maintain the genomic and histopathological characteristics of primary tumors during long-term culture, making them invaluable for large-scale drug discovery. A key advancement was achieved by Takahashi et al. (2019), who developed a high-throughput screening platform using 96- or 384-well plates. Their innovative use of CellPetFT filters enabled uniform organoid fragmentation while preserving spheroid integrity, overcoming a major bottleneck in organoid-based assays and enabling scalable pharmacological testing. Further enhancing their utility, Liu et al. (2021) demonstrated that cryopreservation via a superhydrophobic micropore array chip system maintained identical drug sensitivity profiles in organoids post-thaw. These methodological breakthroughs have accelerated the integration of organoids into preclinical pharmacology, where they now play a pivotal role in studying therapeutic response and resistance mechanisms (Banda et al., 2020; Liu et al., 2021; Chen et al., 2022; Lin et al., 2021).
3.1 PDOs recapitulate NSCLC pathobiology and drug responses
3.1.1 PDOs model NSCLC heterogeneity and drug response
Compared with traditional PDC and PDX models, PDOs better recapitulate tumor heterogeneity and drug response patterns. Kim et al. (2019) established organoids harboring specific oncogenic mutations, which responded predictably to targeted therapies. For instance, BRCA2-mutant organoids showed sensitivity to olaparib, EGFR-mutant organoids responded to erlotinib, and organoids with EGFR mutations coupled with MET amplification exhibited high sensitivity to crizotinib (Levantini et al., 2022; Momozawa et al., 2022; Remon et al., 2023). These findings confirm that transcriptomic signatures in PDOs can serve as reliable indicators for drug sensitivity profiling. Kim SY. et al. (2021) evaluated the efficacy of dabrafenib/trametinib combination therapy using organoids simultaneously harboring EGFR exon 19 deletion, BRAF mutations, and the BRAF G464A variant, validating the therapeutic synergy (Sforza et al., 2022). Subsequent investigations (Li et al., 2022; Rosen et al., 2022) systematically evaluated targeted agents, including poziotinib for ERBB2 exon 20 insertions, pralsetinib for kinase fusions, and afatinib for EGFR L747P mutations—revealing strong correlation between organoid responses and clinical efficacy. Mechanistically, KRAS-mutant NSCLC organoids recapitulated the clinical resistance profile to erlotinib/gefitinib, while afatinib/neratinib overcame this by modulating ERBB2/3 signaling (Papadimitrakopoulou et al., 2016; Rulli et al., 2015). Chen et al. (2020), conducted a comprehensive validation, testing 50 PDO lines against 26 NCCN-recommended agents. Their findings precisely mirrored clinical observations: EGFR exon 20 insertion organoids responded to osimertinib/chemotherapy but resisted gefitinib, c-MET-overexpressing models were osimertinib-sensitive but gefitinib-resistant, and KRAS G12C mutants showed enhanced TKI response with ERBB pathway inhibition, systematically validating PDOs as predictive platforms for precision oncology.
3.1.2 PDOs bridge mechanistic and target discovery in NSCLC
PDOs serve as versatile platforms for both elucidating drug mechanisms and identifying novel therapeutic targets. Ji et al. (2023) demonstrated that NRF2 promotes lung squamous cell carcinoma growth via PI3K-Akt-mTOR signaling, with NRF2 inhibition effectively suppressing this pathway. Similarly, Taverna et al. (2020) utilized short-term lung adenocarcinoma organoids to reveal compensatory crosstalk between AXL and JAK-STAT pathways upon targeted inhibition. These mechanistic insights are complemented by PDOs’ utility in target discovery: β5-integrin was found to suppress gastrin-mediated ferroptosis (Tan et al., 2021), while Su et al. (2023) showed that Src or ceramidase inhibition could reactivate ferroptosis in resistant tumors. Furthermore, Pan et al. (2023) identified Kmt2d deletion as a driver of RTK-RAS signaling through EGFR/ERBB2 upregulation, with combined SHP2 and afatinib inhibition demonstrating potent antitumor effects. Together, these studies highlight PDOs’ dual role in both mechanistic investigation and therapeutic target identification.
3.2 PDOs advance resistance research and NSCLC therapy
PDOs demonstrate significant potential in predicting patient-specific drug responses and elucidating resistance mechanisms. Li YF. et al. (2020) evaluated five natural compounds in PDOs, revealing distinct response patterns: berberine exhibited selective efficacy in PDOs but not in conventional cell lines, while betaine induced resistance in both models. Notably, PDOs also enable real-time monitoring of acquired resistance. Halofuginone (HF) was shown to suppress proliferation, induce cell cycle arrest, and restore cisplatin sensitivity in resistant PDOs, confirming its dual role as a chemosensitizer and pathway inhibitor (Li H. et al., 2021). Further mechanistic studies identified recombinant DCLK1 as a key regulator of cancer stemness via Wnt/β-catenin signaling, driving EGFR-TKI resistance. Yan et al. (2022) demonstrated that DCLK1 inhibition restored TKI sensitivity and synergized with EGFR inhibitors in TKI-resistant PDOs. These findings highlight the role of DCLK1 in promoting stemness and its potential as a therapeutic target in overcoming resistance. Additionally, Weng et al. (2023) developed a novel topoisomerase I inhibitor with potent activity against refractory EGFR-mutant organoids, including those with ex19del/T790M/C797S mutations, and demonstrated synergistic effects with PARP/ATR inhibitors and immunotherapy. These findings underscore PDOs’ utility in identifying drug-tolerant persister (DTP) cells and developing strategies to overcome therapeutic resistance (Mikubo et al., 2021) (Figure 1).
Figure 1. Workflow and translational application of PDOs in NSCLC. Schematic overview depicting the establishment, optimization, and application of patient-derived organoids (PDOs) in non-small cell lung cancer (NSCLC). Primary tumor tissues obtained from surgical or biopsy specimens undergo dissociation and are cultured under 3D conditions to generate NSCLC PDOs. Key challenges include the exclusion of stromal and immune components and inter-tumoral variability, which limit microenvironmental fidelity and clinical relevance. Optimization strategies such as refined tissue processing, tailored culture conditions, and genetic engineering approaches have improved PDO viability and scalability. These models are subsequently utilized in high-throughput drug screening platforms to assess therapeutic efficacy, explore pharmacodynamic mechanisms, model resistance phenotypes, and identify novel therapeutic targets. Mechanistic studies have highlighted the role of NRF2-driven PI3K–Akt–mTOR signaling in tumor growth, while resistance modeling has uncovered DCLK1-mediated Wnt/β-catenin activation and ferroptosis suppression as contributors to EGFR-TKI resistance. The identification of SHP2/ERBB2 axis vulnerabilities further illustrates the potential of PDOs to guide precision oncology in NSCLC.
Resistance mechanisms associated with cancer stem cells are critical for sustained tumor growth and survival. In particular, drug-tolerant persister (DTP) cells evade chemotherapies and targeted agents (Li et al., 2023a). MAPK inhibitors induce PINK1-mediated mitophagy in DTP cells, promoting their survival and proliferation (Li et al., 2023b). When combined with chloroquine, an autophagy inhibitor, MAPK inhibitors regain their cytotoxic effects, indicating that targeting mitophagy could offer a strategy to overcome resistance in DTP populations (Li et al., 2023b; Wang B. et al., 2023). Metabolic alterations also play a significant role in resistance to cancer therapies (Lin et al., 2023). One such example is ferroptosis, a form of regulated necrosis. Ferroptosis suppression by β5-integrin has been linked to chemotherapy resistance in PDOs. SRC or ceramidase inhibition reactivated ferroptosis in chemotherapy-resistant PDOs, thereby reversing drug resistance and providing a potential therapeutic avenue for targeting metabolic escape mechanisms in resistant NSCLC tumors (Beekhof et al., 2023; Luk et al., 2024). Despite these advancements, tumor organoids are not yet clinically approved for guiding therapy. Only when organoids exhibit drug responses consistent with matched patients can they be reliably used in personalized medicine (Xiang et al., 2024). Additionally, tumor heterogeneity complicates the evaluation of organoid predictive value. Thus, while promising, organoid-based drug screening remains a substantial challenge requiring further optimization (Table 1).
Table 1. Pharmacological and translational applications of NSCLC PDOs.
3.3 Next-gen PDOs in immunotherapy response prediction
While patient-derived organoids (PDOs) are invaluable in drug screening, their utility in immunotherapy testing remains limited due to the absence of key immune components that are critical for assessing immune-related responses (Jeong and Kang, 2023; Wang M. et al., 2025). This limitation restricts the ability of PDOs to accurately model the immune microenvironment of tumors, which plays a significant role in the efficacy of immunotherapies, such as immune checkpoint inhibitors (Teijeira et al., 2022). To address this limitation, recent studies have established advanced co-culture platforms that incorporate immune components into PDOs, thereby reconstructing a more immunocompetent tumor microenvironment (Magré et al., 2023; Dao et al., 2022). Immune cells such as peripheral blood mononuclear cells (PBMCs), tumor-infiltrating lymphocytes (TILs), dendritic cells, macrophages, and even chimeric antigen receptor T cells (CAR-T cells) have been successfully integrated into NSCLC PDO systems. These immune cells can be derived either autologously from patient or from allogeneic sources (Sun et al., 2022; Li P. et al., 2024). Co-culture techniques vary, including embedding immune cells into Matrigel with PDOs, overlaying immune cells on organoid surfaces, and using organoid-on-a-chip models to preserve spatial architecture and facilitate direct immune-tumor interaction (Dao et al., 2022; Fang et al., 2023). To overcome this challenge, recent studies have developed co-culture systems that integrate immune cells with PDOs, thus allowing for a more accurate representation of the tumor-immune interaction. These tumor–immune organoid platforms have been used to evaluate immune checkpoint inhibitors, such as PD-1/PD-L1 and CTLA-4 antibodies, providing insights into their efficacy in a more physiologically relevant context (Amato et al., 2025; Ou et al., 2022). For example, Hélène et al. co-cultured NSCLC PDOs with IFN-γ, which led to enhanced immune response assessments and a better understanding of the tumor’s immune evasion mechanisms (Lê et al., 2024). Furthermore, PDO-based immune checkpoint evaluation systems have also been introduced, where immune cells are incorporated into PDO cultures to assess how tumors interact with immune cells and respond to checkpoint inhibition (Yao et al., 2025).
In addition to immune components, the incorporation of other stromal cell types, particularly endothelial cells, has gained attention for reconstructing a more comprehensive tumor microenvironment within PDO systems (Madan et al., 2025; Podaza et al., 2022). Endothelial cells play a pivotal role in angiogenesis, tumor perfusion, and immune cell trafficking, all of which influence drug delivery and response (Xu et al., 2024; Zhao et al., 2021). Advanced organoid-on-a-chip platforms and microfluidic co-culture systems now allow the inclusion of human endothelial cells alongside PDOs, enabling the formation of rudimentary vascular networks within the extracellular matrix (Zhao et al., 2021; Lim et al., 2021). These vascularized organoid models better replicate in vivo gradients of oxygen and nutrients, facilitate dynamic cell–cell interactions, and improve drug penetration modeling. For example, co-culturing NSCLC PDOs with human umbilical vein endothelial cells (HUVECs) under perfusion flow conditions has been shown to support neovascular structure formation and recapitulate tumor angiogenic responses to VEGF inhibitors (Ma et al., 2022b). Additionally, incorporation of pericyte-like stromal cells further enhances the maturation and stability of these networks (Wang X. et al., 2023; Phan et al., 2017).
Notably, studies utilizing TIL-PDO co-cultures have demonstrated that cytotoxic CD8+ T cells infiltrate the organoid structure and mediate cell killing in response to PD-1 blockade, thereby validating the translational potential of such systems (Dijkstra et al., 2018; Magré et al., 2023). Similarly, ALI-PDO platforms preserve endogenous immune infiltrates within the PDO structure, offering a superior representation of in situ immunity (Neal et al., 2018; Thorel et al., 2024). Furthermore, time-lapse imaging and cytokine release assays (IFN-γ, Granzyme B) have been used to functionally assess immune activation and killing capacity (Yuki et al., 2020; Gu et al., 2024). To further enhance the physiological relevance of PDOs and enable dynamic modeling of tumor microenvironments, microfluidic platforms will be an important component of next-generation organoid systems (Szewczyk et al., 2024; Sontheimer-Phelps et al., 2019). Notably, microfluidic devices allow precise spatial and temporal control over cell–cell and cell–matrix interactions (Bhatia and Ingber, 2014; DePalma et al., 2025), which are essential for simulating immune infiltration, angiogenesis, and metastatic dissemination within PDO models (Wang J. et al., 2025). These innovative approaches hold the potential to significantly improve the predictive accuracy of PDOs for immunotherapy responses and guide the development of personalized immunotherapy strategies.
4 Conclusion
Patient-derived organoids represent a paradigm shift in NSCLC research, combining the physiological relevance of in vivo models with the tractability of in vitro systems. This review underscores their superiority over traditional PDC and PDX models in preserving tumor heterogeneity and predicting patient-specific drug responses, as evidenced by high concordance between organoid data and clinical outcomes. Key advancements in organoid generation, particularly through optimized enzymatic digestion, cryopreservation, and engineered mutagenesis techniques, have addressed early challenges in scalability and purity.
Furthermore, PDOs have proven invaluable in dissecting resistance mechanisms and identifying synergistic therapies. For instance, they have elucidated EGFR-TKI tolerance mediated through DCLK1-dependent Wnt signaling activation and revealed effective combination strategies such as SHP2/ERBB inhibition for Kmt2d-deficient tumors. However, critical gaps remain, such as the lack of immune-microenvironment recapitulation and standardized validation protocols for clinical translation. Future efforts must prioritize co-culture systems integrating stromal/immune cells, multicenter biobanking initiatives, and prospective clinical trials correlating PDO-guided therapy with patient survival. As the field evolves, PDOs hold immense promise to revolutionize precision oncology, provided these challenges are systematically addressed to ensure reproducibility and clinical utility.
Author contributions
WT: Writing – original draft. XT: Writing – original draft, Writing – review and editing.
Funding
The authors declare that financial support was received for the research and/or publication of this article. All authors thank Chongqing Youth Vocational and Technical College for their support.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The authors declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Adhikary, P., Chakrabarti, J., Wang, J., Ezuma-Igwe, U., Sun, X., Bastian, W. C., et al. (2025). Spatial biology and organoid technologies reveal a potential therapy-resistant cancer stem cell population in pancreatic ductal adenocarcinoma. bioRxiv, 655586. doi:10.1101/2025.05.22.655586
Amato, L., De Rosa, C., Di Guida, G., Sepe, F., Ariano, A., Capaldo, S., et al. (2025). Addition of metformin to anti-PD-1/PD-L1 drugs activates anti-tumor immune response in peripheral immune cells of NSCLC patients. Cell Death Dis. 16, 286. doi:10.1038/s41419-025-07636-7
Banda, M., McKim, K. L., Myers, M. B., Inoue, M., and Parsons, B. L. (2020). Outgrowth of erlotinib-resistant subpopulations recapitulated in patient-derived lung tumor spheroids and organoids. PLoS One 15, e0238862. doi:10.1371/journal.pone.0238862
Beekhof, R., Bertotti, A., Böttger, F., Vurchio, V., Cottino, F., Zanella, E. R., et al. (2023). Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer. Sci. Transl. Med. 15, eabm3687. doi:10.1126/scitranslmed.abm3687
Bhatia, S. N., and Ingber, D. E. (2014). Microfluidic organs-on-chips. Nat. Biotechnol. 32, 760–772. doi:10.1038/nbt.2989
Broutier, L., Mastrogiovanni, G., Verstegen, M. M., Francies, H. E., Gavarró, L. M., Bradshaw, C. R., et al. (2017). Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat. Med. 23, 1424–1435. doi:10.1038/nm.4438
Canale, M., Virga, A., Angeli, D., Fonzi, E., Gnetti, L., Dubini, A., et al. (2025). Genomic and transcriptomic profiles in smokers and never-smokers lung squamous cell carcinoma patients. Lung Cancer (Auckl) 16, 85–96. doi:10.2147/LCTT.S517580
Chen, J. H., Chu, X. P., Zhang, J. T., Nie, Q., Tang, W. F., Su, J., et al. (2020). Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients. Thorac. Cancer 11, 2279–2290. doi:10.1111/1759-7714.13542
Chen, B., Song, Y., Zhan, Y., Zhou, S., Ke, J., Ao, W., et al. (2022). Fangchinoline inhibits non-small cell lung cancer metastasis by reversing epithelial-mesenchymal transition and suppressing the cytosolic ROS-Related Akt-mTOR signaling pathway. Cancer Lett. 543, 215783. doi:10.1016/j.canlet.2022.215783
Dao, V., Yuki, K., Lo, Y. H., Nakano, M., and Kuo, C. J. (2022). Immune organoids: from tumor modeling to precision oncology. Trends Cancer 8, 870–880. doi:10.1016/j.trecan.2022.06.001
DePalma, T., Rodriguez, M., Kollin, L., Hughes, K., Jones, K., Stagner, E., et al. (2025). A microfluidic blood brain barrier model to study the influence of glioblastoma tumor cells on BBB function. Small 21, e2411361. doi:10.1002/smll.202411361
Dijkstra, K. K., Cattaneo, C. M., Weeber, F., Chalabi, M., van de Haar, J., Fanchi, L. F., et al. (2018). Generation of tumor-reactive T cells by Co-culture of peripheral blood lymphocytes and tumor organoids. Cell 174, 1586–1598.e1512. doi:10.1016/j.cell.2018.07.009
Dijkstra, K. K., Vendramin, R., Karagianni, D., Witsen, M., Gálvez-Cancino, F., Hill, M. S., et al. (2025). Subclonal immune evasion in non-small cell lung cancer. Cancer Cell 43, 1833–1849.e10. doi:10.1016/j.ccell.2025.06.012
Dost, A. F. M., Moye, A. L., Vedaie, M., Tran, L. M., Fung, E., Heinze, D., et al. (2020). Organoids model transcriptional hallmarks of oncogenic KRAS activation in lung epithelial progenitor cells. Cell Stem Cell 27, 663–678.e668. doi:10.1016/j.stem.2020.07.022
Drost, J., and Clevers, H. (2018). Organoids in cancer research. Nat. Rev. Cancer 18, 407–418. doi:10.1038/s41568-018-0007-6
Fang, Z., Li, P., Du, F., Shang, L., and Li, L. (2023). The role of organoids in cancer research. Exp. Hematol. Oncol. 12, 69. doi:10.1186/s40164-023-00433-y
Gu, Z., Wu, Q., Shang, B., Zhang, K., and Zhang, W. (2024). Organoid co-culture models of the tumor microenvironment promote precision medicine. Cancer Innov. 3, e101. doi:10.1002/cai2.101
Han, Y., Lee, T., He, Y., Raman, R., Irizarry, A., Martin, M. L., et al. (2022). The regulation of CD73 in non-small cell lung cancer. Eur. J. Cancer 170, 91–102. doi:10.1016/j.ejca.2022.04.025
Jeong, S. R., and Kang, M. (2023). Exploring tumor-immune interactions in Co-Culture models of T cells and tumor organoids derived from patients. Int. J. Mol. Sci. 24, 14609. doi:10.3390/ijms241914609
Ji, L., Moghal, N., Zou, X., Fang, Y., Hu, S., Wang, Y., et al. (2023). The NRF2 antagonist ML385 inhibits PI3K-mTOR signaling and growth of lung squamous cell carcinoma cells. Cancer Med. 12, 5688–5702. doi:10.1002/cam4.5311
Kim, B., and Park, J. I. (2025). Protocol for establishing genetically engineered murine lung organoids mimicking cell plasticity and regeneration. Star. Protoc. 6, 103911. doi:10.1016/j.xpro.2025.103911
Kim, M., Mun, H., Sung, C. O., Cho, E. J., Jeon, H. J., Chun, S. M., et al. (2019). Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat. Commun. 10, 3991. doi:10.1038/s41467-019-11867-6
Kim, S. K., Kim, Y. H., Park, S., and Cho, S. W. (2021a). Organoid engineering with microfluidics and biomaterials for liver, lung disease, and cancer modeling. Acta Biomater. 132, 37–51. doi:10.1016/j.actbio.2021.03.002
Kim, S. Y., Kim, S. M., Lim, S., Lee, J. Y., Choi, S. J., Yang, S. D., et al. (2021b). Modeling clinical responses to targeted therapies by patient-derived organoids of advanced lung adenocarcinoma. Clin. Cancer Res. 27, 4397–4409. doi:10.1158/1078-0432.CCR-20-5026
Kobayashi, K., and Tan, A. C. (2023). Unraveling the impact of intratumoral heterogeneity on EGFR tyrosine kinase inhibitor resistance in EGFR-mutated NSCLC. Int. J. Mol. Sci. 24, 4126. doi:10.3390/ijms24044126
Kucab, J. E., Hollstein, M., Arlt, V. M., and Phillips, D. H. (2017). Nutlin-3a selects for cells harbouring TP53 mutations. Int. J. Cancer 140, 877–887. doi:10.1002/ijc.30504
Kumamoto, K., Spillare, E. A., Fujita, K., Horikawa, I., Yamashita, T., Appella, E., et al. (2008). Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res. 68, 3193–3203. doi:10.1158/0008-5472.CAN-07-2780
Li, Z., Ma, L., Gao, Z., Wang, X., Che, X., Zhang, P., et al. (2024). Identification and validation of tumor-specific T cell receptors from tumor infiltrating lymphocytes using tumor organoid co-cultures. Cancer Immunol. Immunother. 73, 164. doi:10.1007/s00262-024-03749-8
Lê, H., Deforges, J., Cutolo, P., Lamarque, A., Hua, G., Lindner, V., et al. (2024). Patient-derived tumoroids and proteomic signatures: tools for early drug discovery. Front. Immunol. 15, 1379613. doi:10.3389/fimmu.2024.1379613
Lee, D., Kim, Y., and Chung, C. (2021). Scientific validation and clinical application of lung cancer organoids. Cells 10, 3012. doi:10.3390/cells10113012
LeSavage, B. L., Suhar, R. A., Broguiere, N., Lutolf, M. P., and Heilshorn, S. C. (2022). Next-generation cancer organoids. Nat. Mater 21, 143–159. doi:10.1038/s41563-021-01057-5
Levantini, E., Maroni, G., Del Re, M., and Tenen, D. G. (2022). EGFR signaling pathway as therapeutic target in human cancers. Semin. Cancer Biol. 85, 253–275. doi:10.1016/j.semcancer.2022.04.002
Li, M., and Izpisua Belmonte, J. C. (2019). Organoids - preclinical models of human disease. N. Engl. J. Med. 380, 569–579. doi:10.1056/NEJMra1806175
Li, X., Francies, H. E., Secrier, M., Perner, J., Miremadi, A., Galeano-Dalmau, N., et al. (2018). Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics. Nat. Commun. 9, 2983. doi:10.1038/s41467-018-05190-9
Li, Z., Qian, Y., Li, W., Liu, L., Yu, L., Liu, X., et al. (2020a). Human lung adenocarcinoma-derived organoid models for drug screening. iScience 23, 101411. doi:10.1016/j.isci.2020.101411
Li, Y. F., Gao, Y., Liang, B. W., Cao, X. Q., Sun, Z. J., Yu, J. H., et al. (2020b). Patient-derived organoids of non-small cells lung cancer and their application for drug screening. Neoplasma 67, 430–437. doi:10.4149/neo_2020_190417N346
Li, Z., Yu, L., Chen, D., Meng, Z., Chen, W., and Huang, W. (2021a). Protocol for generation of lung adenocarcinoma organoids from clinical samples. Star. Protoc. 2, 100239. doi:10.1016/j.xpro.2020.100239
Li, H., Zhang, Y., Lan, X., Yu, J., Yang, C., Sun, Z., et al. (2021b). Halofuginone sensitizes lung cancer organoids to cisplatin via suppressing PI3K/AKT and MAPK signaling pathways. Front. Cell Dev. Biol. 9, 773048. doi:10.3389/fcell.2021.773048
Li, B. T., Smit, E. F., Goto, Y., Nakagawa, K., Udagawa, H., Mazières, J., et al. (2022). Trastuzumab deruxtecan in HER2-Mutant non-small-cell lung cancer. N. Engl. J. Med. 386, 241–251. doi:10.1056/NEJMoa2112431
Li, Y., Chen, H., Lu, D., Koeffler, H. P., Zhang, Y., and Yin, D. (2023a). Mitophagy is a novel protective mechanism for drug-tolerant persister (DTP) cancer cells. Autophagy 19, 2618–2619. doi:10.1080/15548627.2023.2177398
Li, Y., Chen, H., Xie, X., Yang, B., Wang, X., Zhang, J., et al. (2023b). PINK1-Mediated mitophagy promotes oxidative phosphorylation and redox homeostasis to induce drug-tolerant persister cancer cells. Cancer Res. 83, 398–413. doi:10.1158/0008-5472.CAN-22-2370
Li, P., Huang, M., Ma, Y., Zhang, Y., and Shi, C. (2024). Novel research model for in vitro immunotherapy: co-culturing tumor organoids with peripheral blood mononuclear cells. Cancer Cell Int. 24, 438. doi:10.1186/s12935-024-03628-3
Liao, W., Zhang, R., Chen, G., Zhu, X., Wu, W., Chen, Z., et al. (2024). Berberine synergises with ferroptosis inducer sensitizing NSCLC to ferroptosis in p53-dependent SLC7A11-GPX4 pathway. Biomed. Pharmacother. 176, 116832. doi:10.1016/j.biopha.2024.116832
Lim, J., Ching, H., Yoon, J. K., Jeon, N. L., and Kim, Y. (2021). Microvascularized tumor organoids-on-chips: advancing preclinical drug screening with pathophysiological relevance. Nano Converg. 8, 12. doi:10.1186/s40580-021-00261-y
Lim, S. M., Schalm, S. S., Lee, E. J., Park, S., Conti, C., Millet, Y. A., et al. (2024). BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer. Ther. Adv. Med. Oncol. 16, 17588359241280689. doi:10.1177/17588359241280689
Lin, S., Li, Y., Wang, D., Huang, C., Marino, D., Bollt, O., et al. (2021). Fascin promotes lung cancer growth and metastasis by enhancing glycolysis and PFKFB3 expression. Cancer Lett. 518, 230–242. doi:10.1016/j.canlet.2021.07.025
Lin, Z., Li, J., Zhang, J., Feng, W., Lu, J., Ma, X., et al. (2023). Metabolic reprogramming driven by IGF2BP3 promotes acquired resistance to EGFR inhibitors in non-small cell lung cancer. Cancer Res. 83, 2187–2207. doi:10.1158/0008-5472.CAN-22-3059
Liu, Q., Zhao, T., Wang, X., Chen, Z., Hu, Y., and Chen, X. (2021). In situ vitrification of lung cancer organoids on a microwell array. Micromachines (Basel) 12, 624. doi:10.3390/mi12060624
Luk, I. S., Bridgwater, C. M., Yu, A., Boila, L. D., Yáñez-Bartolomé, M., Lampano, A. E., et al. (2024). SRC inhibition enables formation of a growth suppressive MAGI1-PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma. Sci. Transl. Med. 16, eadj7685. doi:10.1126/scitranslmed.adj7685
Ma, X., Li, H., Zhu, S., Hong, Z., Kong, W., and Yuan, Q., Angiorganoid: vitalizing the organoid with blood vessels. (2022a). Vasc. Biol. 4:R44–R57. doi:10.1530/VB-22-0001
Ma, H. C., Zhu, Y. J., Zhou, R., Yu, Y. Y., Xiao, Z. Z., and Zhang, H. B. (2022b). Lung cancer organoids, a promising model still with long way to go. Crit. Rev. Oncol. Hematol. 171, 103610. doi:10.1016/j.critrevonc.2022.103610
Ma, J., Li, S., Zhang, X., Zhao, P., Zhao, B., Yue, J., et al. (2025a). Lung cancer organoids in translational research: bridging basic science, drug development, and clinical therapeutics. Crit. Rev. Oncol. Hematol. 214, 104840. doi:10.1016/j.critrevonc.2025.104840
Ma, X., Ma, Z., Qi, X., Zhang, X., Liu, X., Liu, X., et al. (2025b). Identification of a novel src inhibitor K882 derived from quinazoline-based stilbenes with anti-NSCLC effect. Bioorg Chem. 156, 108185. doi:10.1016/j.bioorg.2025.108185
Madan, A., Saini, R., Dhiman, N., Juan, S.-H., and Satapathy, MKJO (2025). Organoids as next-generation models for tumor heterogeneity, personalized therapy, and cancer research: advancements, applications, and future directions. Future Dir. 4, 23. doi:10.3390/organoids4040023
Magré, L., Verstegen, M. M. A., Buschow, S., van der Laan, L. J. W., Peppelenbosch, M., and Desai, J. (2023). Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies. J. Immunother. Cancer 11, e006290. doi:10.1136/jitc-2022-006290
Mikubo, M., Inoue, Y., Liu, G., and Tsao, M. S. (2021). Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy. J. Thorac. Oncol. 16, 1798–1809. doi:10.1016/j.jtho.2021.07.017
Momozawa, Y., Sasai, R., Usui, Y., Shiraishi, K., Iwasaki, Y., Taniyama, Y., et al. (2022). Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants. JAMA Oncol. 8, 871–878. doi:10.1001/jamaoncol.2022.0476
Nakamura, H., Sugano, M., Miyashita, T., Hashimoto, H., Ochiai, A., Suzuki, K., et al. (2019). Organoid culture containing cancer cells and stromal cells reveals that podoplanin-positive cancer-associated fibroblasts enhance proliferation of lung cancer cells. Lung Cancer 134, 100–107. doi:10.1016/j.lungcan.2019.04.007
Nam, C., Ziman, B., Sheth, M., Zhao, H., and Lin, D. C. (2022). Genomic and epigenomic characterization of tumor organoid models. Cancers (Basel) 14, 4090. doi:10.3390/cancers14174090
Naranjo, S., Cabana, C. M., LaFave, L. M., Romero, R., Shanahan, S. L., Bhutkar, A., et al. (2022). Modeling diverse genetic subtypes of lung adenocarcinoma with a next-generation alveolar type 2 organoid platform. Genes Dev. 36, 936–949. doi:10.1101/gad.349659.122
Navarro, P., Grazioso, T. P., Barquín, A., Barba, M., Yagüe, M., Millán, C., et al. (2025). Multicenter study correlating molecular characteristics and clinical outcomes of cancer cases with patient-derived organoids. J. Exp. Clin. Cancer Res. 44, 182. doi:10.1186/s13046-025-03437-0
Neal, J. T., Li, X., Zhu, J., Giangarra, V., Grzeskowiak, C. L., Ju, J., et al. (2018). Organoid modeling of the tumor immune microenvironment. Cell 175, 1972–1988.e1916. doi:10.1016/j.cell.2018.11.021
Nousias, O., Mandell, J. D., Anderson, K. S., and Townsend, J. P. (2025). Precision projections of the delay of resistance mutations in non-small cell lung cancer via suppression of APOBEC. Lung Cancer 202, 108487. doi:10.1016/j.lungcan.2025.108487
Ou, L., Wang, H., Huang, H., Zhou, Z., Lin, Q., Guo, Y., et al. (2022). Preclinical platforms to study therapeutic efficacy of human γδ T cells. Clin. Transl. Med. 12, e814. doi:10.1002/ctm2.814
Pan, Y., Han, H., Hu, H., Wang, H., Song, Y., Hao, Y., et al. (2023). KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition. Cancer Cell 41, 88–105.e108. doi:10.1016/j.ccell.2022.11.015
Papadimitrakopoulou, V., Lee, J. J., Wistuba, I. I., Tsao, A. S., Fossella, F. V., Kalhor, N., et al. (2016). The BATTLE-2 study: a biomarker-integrated targeted therapy study in previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 34, 3638–3647. doi:10.1200/JCO.2015.66.0084
Phan, D. T., Wang, X., Craver, B. M., Sobrino, A., Zhao, D., Chen, J. C., et al. A vascularized and perfused organ-on-a-chip platform for large-scale drug screening applications. (2017). Lab Chip, 17:511–520. doi:10.1039/c6lc01422d
Podaza, E., Kuo, H. H., Nguyen, J., Elemento, O., and Martin, M. L. (2022). Next generation patient derived tumor organoids. Transl. Res. 250, 84–97. doi:10.1016/j.trsl.2022.08.003
Remon, J., Hendriks, L. E. L., Mountzios, G., García-Campelo, R., Saw, S. P. L., Uprety, D., et al. (2023). MET alterations in NSCLC-current perspectives and future challenges. J. Thorac. Oncol. 18, 419–435. doi:10.1016/j.jtho.2022.10.015
Rosen, E. Y., Won, H. H., Zheng, Y., Cocco, E., Selcuklu, D., Gong, Y., et al. (2022). The evolution of RET inhibitor resistance in RET-Driven lung and thyroid cancers. Nat. Commun. 13, 1450. doi:10.1038/s41467-022-28848-x
Rossi, R., De Angelis, M. L., Xhelili, E., Sette, G., Eramo, A., De Maria, R., et al. (2022). Lung cancer organoids: the rough path to personalized medicine. Cancers (Basel) 14, 3703. doi:10.3390/cancers14153703
Rulli, E., Marabese, M., Torri, V., Farina, G., Veronese, S., Bettini, A., et al. (2015). Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. Ann. Oncol. 26, 2079–2084. doi:10.1093/annonc/mdv318
Sachs, N., Papaspyropoulos, A., Zomer-van Ommen, D. D., Heo, I., Böttinger, L., Klay, D., et al. (2019). Long-term expanding human airway organoids for disease modeling. Embo J. 38, e100300. doi:10.15252/embj.2018100300
Sforza, V., Palumbo, G., Cascetta, P., Carillio, G., Manzo, A., Montanino, A., et al. (2022). BRAF inhibitors in non-small cell lung cancer. Cancers (Basel) 14, 4863. doi:10.3390/cancers14194863
Shi, R., Radulovich, N., Ng, C., Liu, N., Notsuda, H., Cabanero, M., et al. (2020). Organoid cultures as preclinical models of non-small cell lung cancer. Clin. Cancer Res. 26, 1162–1174. doi:10.1158/1078-0432.CCR-19-1376
Song, X., Zhou, Z., Elmezayen, A., Wu, R., Yu, C., Gao, B., et al. (2024). SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition. Sci. Adv. 10, eadq4274. doi:10.1126/sciadv.adq4274
Sontheimer-Phelps, A., Hassell, B. A., and Ingber, D. E. (2019). Modelling cancer in microfluidic human organs-on-chips. Nat. Rev. Cancer 19, 65–81. doi:10.1038/s41568-018-0104-6
Su, L., Chen, Y., Huang, C., Wu, S., Wang, X., Zhao, X., et al. (2023). Targeting src reactivates pyroptosis to reverse chemoresistance in lung and pancreatic cancer models. Sci. Transl. Med. 15, eabl7895. doi:10.1126/scitranslmed.abl7895
Sun, C. P., Lan, H. R., Fang, X. L., Yang, X. Y., and Jin, K. T. (2022). Organoid models for precision cancer immunotherapy. Front. Immunol. 13, 770465. doi:10.3389/fimmu.2022.770465
Szewczyk, K., Jiang, L., Khawaja, H., Miranti, C. K., and Zohar, Y. (2024). Microfluidic applications in prostate cancer research. Micromachines (Basel) 15, 1195. doi:10.3390/mi15101195
Takahashi, N., Hoshi, H., Higa, A., Hiyama, G., Tamura, H., Ogawa, M., et al. (2019). An in vitro system for evaluating molecular targeted drugs using lung patient-derived tumor organoids. Cells 8, 481. doi:10.3390/cells8050481
Tamura, H., Higa, A., Hoshi, H., Hiyama, G., Takahashi, N., Ryufuku, M., et al. (2018). Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues. Oncol. Rep. 40, 635–646. doi:10.3892/or.2018.6501
Tan, Y., Chen, Q., Li, X., Zeng, Z., Xiong, W., Li, G., et al. (2021). Pyroptosis: a new paradigm of cell death for fighting against cancer. J. Exp. Clin. Cancer Res. 40, 153. doi:10.1186/s13046-021-01959-x
Taverna, J. A., Hung, C. N., DeArmond, D. T., Chen, M., Lin, C. L., Osmulski, P. A., et al. (2020). Single-cell proteomic profiling identifies combined AXL and JAK1 inhibition as a novel therapeutic strategy for lung cancer. Cancer Res. 80, 1551–1563. doi:10.1158/0008-5472.CAN-19-3183
Teijeira, A., Migueliz, I., Garasa, S., Karanikas, V., Luri, C., Cirella, A., et al. (2022). Three-dimensional Colon cancer organoids model the response to CEA-CD3 T-cell engagers. Theranostics 12, 1373–1387. doi:10.7150/thno.63359
Thorel, L., Perréard, M., Florent, R., Divoux, J., Coffy, S., Vincent, A., et al. (2024). Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology. Exp. Mol. Med. 56, 1531–1551. doi:10.1038/s12276-024-01272-5
Wang, E., Xiang, K., Zhang, Y., and Wang, X. F. (2022). Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): new opportunities in establishing faithful pre-clinical cancer models. J. Natl. Cancer Cent. 2, 263–276. doi:10.1016/j.jncc.2022.10.001
Wang, B., Li, L., and Yu, R. (2023a). Exosomes from adipose-derived stem cells suppress the progression of chronic endometritis. Cell Transpl. 32, 9636897231173736. doi:10.1177/09636897231173736
Wang, X., Bijonowski, B. M., and Kurniawan, NAJO (2023b). Vascularizing organoids to promote long-term organogenesis on a chip. Organoids 2, 239–255. doi:10.3390/organoids2040019
Wang, M., Wang, Y., Pan, X., Wang, B., Wang, Y., Luo, X., et al. (2025a). Acquired resistance to immunotherapy by physical barriers with cancer cell-expressing collagens in non-small cell lung cancer. Proc. Natl. Acad. Sci. U. S. A. 122, e2500019122. doi:10.1073/pnas.2500019122
Wang, J., Tao, X., Zhu, J., Dai, Z., Du, Y., Xie, Y., et al. (2025b). Tumor organoid-immune co-culture models: exploring a new perspective of tumor immunity. Cell Death Discov. 11, 195. doi:10.1038/s41420-025-02407-x
Weng, W., Meng, T., Zhao, Q., Shen, Y., Fu, G., Shi, J., et al. (2023). Antibody-exatecan conjugates with a novel self-immolative moiety overcome resistance in Colon and lung cancer. Cancer Discov. 13, 950–973. doi:10.1158/2159-8290.CD-22-1368
Xiang, D., He, A., Zhou, R., Wang, Y., Xiao, X., Gong, T., et al. (2024). Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development. Theranostics 14, 3300–3316. doi:10.7150/thno.96027
Xu, Y., Xin, W., Yan, C., Shi, Y., Li, Y., Hu, Y., et al. (2022). Organoids in lung cancer: a teenager with infinite growth potential. Lung Cancer 172, 100–107. doi:10.1016/j.lungcan.2022.08.006
Xu, H., Wen, J., Yang, J., Zhou, S., Li, Y., Xu, K., et al. (2024). Tumor-microenvironment-on-a-chip: the construction and application. Cell Commun. Signal 22, 515. doi:10.1186/s12964-024-01884-4
Yan, R., Fan, X., Xiao, Z., Liu, H., Huang, X., Liu, J., et al. (2022). Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/β-Catenin activity and cancer stemness. Cancer Lett. 531, 83–97. doi:10.1016/j.canlet.2022.01.030
Yao, Y., Li, B., Wang, J., Chen, C., Gao, W., and Li, C. (2025). A novel HVEM-Fc recombinant protein for lung cancer immunotherapy. J. Exp. Clin. Cancer Res. 44, 62. doi:10.1186/s13046-025-03324-8
Yuki, K., Cheng, N., Nakano, M., and Kuo, C. J. (2020). Organoid models of tumor immunology. Trends Immunol. 41, 652–664. doi:10.1016/j.it.2020.06.010
Zhang, P., Zhang, J., Bian, S., Chen, Z., Hu, Y., Hu, R., et al. (2016). High-throughput superhydrophobic microwell arrays for investigating multifactorial stem cell niches. Lab. Chip 16, 2996–3006. doi:10.1039/c6lc00331a
Keywords: lung cancer, organoids, tumor microenvironment, high-throughput drug screening, drug resistance, precision therapy
Citation: Tang W and Tian X (2026) Patient-derived organoids in non-small cell lung cancer: advances in drug sensitivity testing. Front. Pharmacol. 16:1639268. doi: 10.3389/fphar.2025.1639268
Received: 01 June 2025; Accepted: 20 November 2025;
Published: 05 January 2026.
Edited by:
Shiv K. Gupta, Mayo Clinic, United StatesReviewed by:
Yi Cao, University of South China, ChinaCopyright © 2026 Tang and Tian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xudong Tian, MTg4ODM5MzczMjZAMTYzLmNvbQ==
†ORCID: Xudong Tian, orcid.org/0009-0007-0150-7283